UniProt O95835 · PDB · AlphaFold · Substrate: SGKtide · Clone: Catalytic (aa589-1130end)medium-confidence target
Top inhibitors
| # | Drug | Inhibition | Residual | KISS | Gini |
|---|---|---|---|---|---|
| 1 | Netarsudil | 93.8% | 6.2% | 93.22 | 0.676 |
| 2 | Capivasertib | 87.7% | 12.3% | 96.48 | 0.644 |
| 3 | Baricitinib | 86.4% | 13.6% | 97.99 | 0.616 |
| 4 | Ruxolitinib | 71.2% | 28.8% | 98.25 | 0.592 |
| 5 | Pacritinib | 68.3% | 31.7% | 88.64 | 0.452 |
| 6 | Midostaurin | 64.3% | 35.7% | 78.64 | 0.500 |
| 7 | Darovasertib | 54.5% | 45.5% | 96.99 | 0.719 |
| 8 | Defactinib | 44.6% | 55.4% | 92.68 | 0.450 |
| 9 | Brigatinib | 38.6% | 61.4% | 82.96 | 0.513 |
| 10 | Abrocitinib | 29.6% | 70.4% | 99.50 | 0.581 |
| 11 | Gilteritinib | 26.9% | 73.1% | 88.97 | 0.506 |
| 12 | Abemaciclib | 26.6% | 73.4% | 91.48 | 0.563 |
| 13 | Sunitinib | 23.7% | 76.3% | 91.73 | 0.524 |
| 14 | Pralsetinib | 20.0% | 80.0% | 93.43 | 0.643 |
| 15 | Pirtobrutinib | 16.2% | 83.8% | 99.49 | 0.656 |
| 16 | Upadacitinib | 15.7% | 84.3% | 97.98 | 0.663 |
| 17 | Ponatinib | 12.1% | 87.9% | 78.23 | 0.534 |
| 18 | Erdafitinib | 11.3% | 88.7% | 95.71 | 0.737 |
| 19 | Repotrectinib | 9.6% | 90.4% | 84.21 | 0.608 |
| 20 | Erlotinib | 9.2% | 90.8% | 99.75 | 0.695 |
Paralog block
No paralog group registered for this kinase.
EMT expression
- Mesenchymal log2(TPM+1): 3.08
- Epithelial log2(TPM+1): 2.95
- Fold change: 0.13
- Status: No significant change
High-confidence drugs
- Netarsudil — inh 93.8% · KISS 36.68
- Baricitinib — inh 86.4% · KISS 32.36
- Ruxolitinib — inh 71.2% · KISS 19.69
Selectivity landscape vs inhibition on LATS1
Each point is one of the 92 approved drugs; color = inhibition % on LATS1.
3D structure
Embedded NGL viewer pulls a representative PDB entry (or AlphaFold model if no experimental structure is registered). Heavy bundle — loaded only on demand.
Annotations
Sign in to read and post annotations.
Loading…